Early Clinical Development of Lufotrelvir as a Potential Therapy for COVID-19.
Allais C, Bernhardson D, Brown AR, Chinigo GM, Desrosiers JN, DiRico KJ, Hotham I, Jones BP, Kulkarni SA, Lewis CA, Lira R, Loach RP, Morse PD, Mousseau JJ, Perry MA, Peng Z, Place DW, Rane AM, Samp L, Singer RA, Wang Z, Weisenburger GA, Yayla HG, Zanghi JM.
Allais C, et al. Among authors: singer ra.
Org Process Res Dev. 2023 Feb 3:acs.oprd.2c00375. doi: 10.1021/acs.oprd.2c00375. Online ahead of print.
Org Process Res Dev. 2023.
PMID: 37552749
Review.